The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
January 25th 2023
An analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition showed that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib.
Predictors of Severe COVID-19 Infection, Mortality in Patients With MM, AL Identified
November 29th 2022Their findings, say the researchers, offer useful insights into the outcomes and risks of severe disease and mortality in patients who have multiple myeloma (MM) or amyloidosis (AL) with underlying monoclonal gammopathy who contract COVID-19.
Read More
CAR T-Cell Therapy Can Work as Salvage Treatment in Relapsed MM Following BCMA-Directed CAR T
November 18th 2022New data show patients treated with chimeric antigen receptor (CAR) T-cell therapy as salvage therapy tended to have meaningful results despite treatment failure following B-cell maturation antigen (BCMA) CAR T.
Read More
EHR Data Show MM Treatment Burden Higher Than Chronic Lymphoid Leukemia
November 14th 2022This new study shows how using electronic health record (EHR) data can objectively quantify patient treatment burden among individuals who have multiple myeloma (MM) compared with patient-reported outcomes, which can be subject to recall bias.
Read More
Dr Joseph Alvarnas: Cancer Care Equity Act Meets the Needs of Patients With Advanced Disease
November 12th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke on how the California Cancer Care Equity Act will allow oncologists to escalate the care of patients with advanced cancers toward established centers that can better meet their needs, as well as implications from the decision to exclude genomic testing coverage in the bill.
Read More
Bhavesh Shah Discusses Expanding Access for BCMA Bispecific Antibody
November 7th 2022Bhavesh Shah, RPh, BCOP, chief pharmacy officer and director of specialty and hematology/oncology pharmacy at Boston Medical Center, talks about what oncology agents in the pipeline he hopes to see become available.
Read More
Dr Ajay Nooka Discusses Cost Savings and QOL Benefits of MRD-Directed Treatment Decisions
September 16th 2022Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Read More
Could CAR-NK Cells Using Cord Blood Offer a Treatment for Multiple Myeloma?
September 9th 2022For several years, investigators have examined the potential for allogenic natural killer (NK) cells as an alternative for “off-the-shelf” chimeric antigen receptor (CAR) treatments. New study results presented at the International Myeloma Society (IMS) meeting showed CD38 CAR-NK cells significantly reduced the tumor burden—and improved survival
Read More
How Should MRD Results Be Used? Experts Don’t Necessarily Agree, Dr Ajay Nooka Says
September 5th 2022Everyone agrees that minimal residual disease (MRD) is the best prognostic tool for multiple myeloma, but there is disagreement on how to use the MRD results, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Read More
Dr Ajay Nooka Discusses Use of MRD Testing in Multiple Myeloma at Emory
September 2nd 2022Minimal residual disease (MRD) testing is used to understand the depth of response, but currently the data at Emory are not used to make treatment decisions, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Read More
Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS
August 10th 2022Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.
Read More
NGF-Based MRD Assessment Demonstrates Potential to Predict MM Disease Progression
August 4th 2022Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.
Read More